JP2017503511A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503511A5
JP2017503511A5 JP2016545971A JP2016545971A JP2017503511A5 JP 2017503511 A5 JP2017503511 A5 JP 2017503511A5 JP 2016545971 A JP2016545971 A JP 2016545971A JP 2016545971 A JP2016545971 A JP 2016545971A JP 2017503511 A5 JP2017503511 A5 JP 2017503511A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016545971A
Other languages
English (en)
Japanese (ja)
Other versions
JP6709733B2 (ja
JP2017503511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/011269 external-priority patent/WO2015106290A1/en
Publication of JP2017503511A publication Critical patent/JP2017503511A/ja
Publication of JP2017503511A5 publication Critical patent/JP2017503511A5/ja
Application granted granted Critical
Publication of JP6709733B2 publication Critical patent/JP6709733B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016545971A 2014-01-13 2015-01-13 内在化部分 Expired - Fee Related JP6709733B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461926863P 2014-01-13 2014-01-13
US201461926865P 2014-01-13 2014-01-13
US61/926,863 2014-01-13
US61/926,865 2014-01-13
US201462042755P 2014-08-27 2014-08-27
US201462042771P 2014-08-27 2014-08-27
US62/042,771 2014-08-27
US62/042,755 2014-08-27
PCT/US2015/011269 WO2015106290A1 (en) 2014-01-13 2015-01-13 Internalizing moieties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020029459A Division JP2020096636A (ja) 2014-01-13 2020-02-25 内在化部分

Publications (3)

Publication Number Publication Date
JP2017503511A JP2017503511A (ja) 2017-02-02
JP2017503511A5 true JP2017503511A5 (cg-RX-API-DMAC10.html) 2018-02-15
JP6709733B2 JP6709733B2 (ja) 2020-06-17

Family

ID=53524430

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016545971A Expired - Fee Related JP6709733B2 (ja) 2014-01-13 2015-01-13 内在化部分
JP2020029459A Pending JP2020096636A (ja) 2014-01-13 2020-02-25 内在化部分

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020029459A Pending JP2020096636A (ja) 2014-01-13 2020-02-25 内在化部分

Country Status (7)

Country Link
US (2) US10221250B2 (cg-RX-API-DMAC10.html)
EP (2) EP3094646B1 (cg-RX-API-DMAC10.html)
JP (2) JP6709733B2 (cg-RX-API-DMAC10.html)
AU (1) AU2015204446A1 (cg-RX-API-DMAC10.html)
CA (1) CA2936102A1 (cg-RX-API-DMAC10.html)
HK (1) HK1231492A1 (cg-RX-API-DMAC10.html)
WO (1) WO2015106290A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーYale University 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス, エルエルシー ポンぺ病の処置のための方法および組成物
WO2015106290A1 (en) 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
WO2015134607A1 (en) 2014-03-04 2015-09-11 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
CA2995673A1 (en) * 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
CA3036524A1 (en) * 2016-09-09 2018-03-15 Valerion Therapeutics, Llc Methods and compositions for treatment of lafora disease
KR20240148849A (ko) * 2017-03-20 2024-10-11 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
US11613590B2 (en) * 2017-07-17 2023-03-28 Nucleus Therapeutics Pty. Ltd Binding proteins 1
US20210137960A1 (en) 2018-02-01 2021-05-13 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
JP2021518840A (ja) * 2018-03-15 2021-08-05 バレリオン セラピューティクス, エルエルシー ポリグルコサン障害の処置のための方法及び組成物
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
BR112021003823A2 (pt) * 2018-08-31 2021-05-25 Yale University composição, composição farmacêutica e método para modificar o genoma de uma célula
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR20220101073A (ko) 2019-08-30 2022-07-19 예일 유니버시티 핵산을 세포로 전달하기 위한 조성물 및 방법
WO2021077070A1 (en) 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
WO2022047424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
CN117295753A (zh) * 2020-12-04 2023-12-26 基那奥生物公司 用于将核酸递送到细胞的组合物和方法
KR20230154921A (ko) 2021-03-03 2023-11-09 예일 유니버시티 골격근 질환을 치료하기 위한 조성물 및 방법
KR20240043747A (ko) 2021-07-02 2024-04-03 예일 유니버시티 암을 치료하기 위한 조성물 및 방법
JP2024532621A (ja) 2021-08-31 2024-09-05 イエール ユニバーシティ がんを治療するための組成物および方法
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2023168401A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for treating disease
AU2023228912A1 (en) * 2022-03-03 2024-09-19 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
EP4584292A1 (en) 2022-09-09 2025-07-16 Yale University Proteolysis targeting antibodies and methods of use thereof
KR20250137203A (ko) 2022-12-27 2025-09-17 예일 유니버시티 항체 약물 접합체
EP4655007A1 (en) 2023-01-23 2025-12-03 Yale University Antibody oligonucleotide conjugates
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2024259300A2 (en) * 2023-06-15 2024-12-19 Caris Science, Inc. Compositions and methods for targeting extracellular dna
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
WO2026011073A1 (en) * 2024-07-03 2026-01-08 Yale University Antibody drug conjugates

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1997032602A1 (en) 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
AU2008207948A1 (en) 2007-01-22 2008-07-31 The United States Government As Represented By The Department Of Veterans Affairs Use of antibody conjugates
JP2010527618A (ja) 2007-05-24 2010-08-19 アメリカ合衆国 ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
CA2777486A1 (en) 2008-10-15 2010-04-22 4S3 Bioscience Inc. Methods and compositions for treatment of myotonic dystrophy
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
GB2476671B (en) 2010-01-04 2014-11-26 Plastic Logic Ltd Touch-sensing systems
JP5240316B2 (ja) 2010-10-26 2013-07-17 株式会社デンソー 車両乗員非操作運転システム
WO2012145125A1 (en) 2011-03-25 2012-10-26 4S3 Bioscience Inc. Targeted radionuclides
JP6178785B2 (ja) * 2011-04-01 2017-08-09 イェール ユニバーシティーYale University 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
KR20140035357A (ko) 2011-04-05 2014-03-21 셰브런 오로나이트 컴퍼니 엘엘씨 저점도 선박 실린더 윤활유 조성물
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US20150152170A1 (en) 2012-05-23 2015-06-04 Valerion Therapeutics, Llc Methods for increasing muscle contractility
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス, エルエルシー ポンぺ病の処置のための方法および組成物
WO2014130722A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of forbes-cori disease
WO2015106290A1 (en) 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
EP3154570A4 (en) 2014-06-13 2017-12-27 Valerion Therapeutics, LLC Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer

Similar Documents

Publication Publication Date Title
JP6978468B2 (ja) Vegfを阻害する安定かつ可溶性の抗体
JP7577435B2 (ja) Cldn18.2及びcd3に対する抗体コンストラクト
JP6910380B2 (ja) 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
KR101523788B1 (ko) 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
JP4845732B2 (ja) 抗vegf抗体
JP6726168B2 (ja) Cdh19およびcd3に対する抗体コンストラクト
JP7671326B2 (ja) 抗フリズルド抗体及び使用方法
JP5738294B2 (ja) 抗vegfモノクローナル抗体およびその抗体を含む薬学的組成物
JP5823858B2 (ja) 抗vegf抗体
KR20200074201A (ko) Alk-1 및 bmpr-2에 결합하는 이중특이적 항체
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
JP6328231B2 (ja) 抗vegf抗体およびそれを含む癌または血管新生関連疾患を予防、診断、または治療するための医薬組成物
TWI685502B (zh) 新穎抗人類Tie2抗體
US20180127509A1 (en) Internalizing moieties for treatment of cancer
JP2020510658A (ja) 操作されたヘテロ二量体タンパク質
NO345763B1 (no) Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering.
MX2014009565A (es) Anticuerpos monocatenarios y otros heteromultimeros.
KR20220082007A (ko) 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
KR20200105493A (ko) Muc17 및 cd3에 대한 이중특이적 항체 구축물
CN116249547B (zh) 脑特异性血管生成抑制剂1(bai1)抗体及其用途
CN104650229A (zh) 抗-kdr抗体和使用方法
JPWO2019124461A1 (ja) 抗体断片多量体分子、医薬品、抗腫瘍剤、自己免疫疾患治療剤及び抗体断片多量体分子の作製方法
HK40073145A (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
CN115819605A (zh) 一种连接抗体的抗原结合功能域的方法及其应用
HK40073145B (en) Antibodies against the poliovirus receptor (pvr) and uses thereof